TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.10 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 INCREASING NUMBER OF CLINICAL TRIALS
3.1.2 GROWING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS
3.1.3 INCREASE IN R & D EXPENDITURE BY PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
3.1.4 INCREASE IN THE NUMBER OF ADVERSE DRUG REACTIONS (ADRS)
3.2 RESTRAINT
3.2.1 HIGH COST OF DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE
3.3 OPPORTUNITIES
3.3.1 AUTOMATION IN DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE
3.3.2 RESEARCH COLLABORATIONS AND PARTNERSHIPS
3.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS
3.4 CHALLENGE
3.4.1 THE MISREPORTING AND MISCODING OF ADVERSE EVENTS
4 EXECUTIVE SUMMARY
5 MIDDLE EAST AND AFRICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET, BY TYPE
5.1 OVERVIEW
5.2 SOFTWARE
5.2.1 ADVERSE EVENT REPORTING SOFTWARE
5.2.1.1 ON-PREMISE
5.2.1.2 CLOUD BASED
5.2.2 DRUG SAFETY AUDITS SOFTWARE
5.2.2.1 ON-PREMISE
5.2.2.2 CLOUD BASED
5.2.3 DATA MANAGEMENT SOFTWARE
5.2.3.1 ON-PREMISE
5.2.3.2 CLOUD BASED
5.2.4 FULLY INTEGRATED SOFTWARE
5.2.4.1 ON-PREMISE
5.2.4.2 CLOUD BASED
5.2.5 ISSUE TRACKING SOFTWARE
5.2.5.1 ON-PREMISE
5.2.5.2 CLOUD BASED
5.2.6 CLINICAL TRIAL MANAGEMENT SOLUTION
5.2.6.1 ON-PREMISE
5.2.6.2 CLOUD BASED
5.2.7 REGULATORY CONTENT AND INFORMATION MANAGEMENT SOFTWARE
5.2.7.1 ON-PREMISE
5.2.7.2 CLOUD BASED
5.2.8 MEDICAL AFFAIRS SOFTWARE
5.2.8.1 ON-PREMISE
5.2.8.2 CLOUD BASED
5.2.9 OTHERS
5.2.9.1 ON-PREMISE
5.2.9.2 CLOUD BASED
5.3 SERVICES
5.3.1 CLINICAL DATA MANAGEMENT
5.3.1.1 DATA ENTRY AND CASE PROCESSING
5.3.1.2 CLINICAL TRIAL MONITORING
5.3.1.3 CLINICAL TRIAL SAFETY SUBMISSIONS
5.3.1.4 CASE PROCESSING (SAES)
5.3.1.5 OTHERS
?
5.3.2 DRUG SAFETY SOLUTIONS
5.3.2.1 QUALITY AND MEDICAL REVIEW
5.3.2.2 LITERATURE AND SOCIAL MEDIA MONITORING
5.3.2.3 SAFETY DATABASE
5.3.2.4 INDIVIDUAL CASE STUDY REPORT
5.3.2.5 PERIODIC REPORTS
5.3.2.6 MEDICAL LITERATURE SEARCH
5.3.2.7 SIGNAL DETECTION
5.3.2.8 EXPEDITED REPORTS
5.3.2.9 OTHERS
5.3.3 AGGREGATE SAFETY REPORTING
5.3.4 REGULATORY SERVICES
5.3.4.1 SAFETY REGULATORY SUBMISSIONS
5.3.4.2 POST-MARKETING SURVEILLANCE
5.3.4.3 MEDICAL DEVICE VIGILANCE
5.3.4.4 REGULATORY CONSULTING
5.3.4.5 OTHERS
5.3.5 RISK MANAGEMENT SERVICES
5.3.6 MEDICAL INFORMATION CALL CENTER SERVICES
5.3.7 AUDIT SERVICES
5.3.8 TRAINING SUPPORT SERVICES
5.3.9 OTHERS
6 MIDDLE EAST AND AFRICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET, BY END USERS
6.1 OVERVIEW
6.2 PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRIES
6.3 CONTRACT RESEARCH ORGANIZATIONS (CROS)
6.4 HOSPITALS
6.5 KPOS/BPOS
6.6 HEALTHCARE PROVIDERS
6.7 OTHERS
7 MIDDLE EAST AND AFRICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET, BY DISTRIBUTION CHANNEL
7.1 OVERVIEW
7.2 DIRECT SALES
7.3 RETAIL SALES
8 MIDDLE EAST AND AFRICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET, BY GEOGRAPHY
8.1 MIDDLE EAST AND AFRICA
8.1.1 UAE
8.1.2 SAUDI ARABIA
8.1.3 KUWAIT
8.1.4 SOUTH AFRICA
8.1.5 REST OF MIDDLE EAST AND AFRICA
9 MIDDLE EAST AND AFRICA DRUG SAFETY SOLUTIONS & PHARMACOVIGILANCE MARKET, COMPANY LANDSCAPE
9.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
10 COMPANY PROFILE
10.1 SYNEOS HEALTH
10.1.1 COMPANY SNAPSHOT
10.1.2 REVENUE ANALYSIS
10.1.3 COMPANY SHARE ANALYSIS
10.1.4 SOLUTION PORTFOLIO
10.1.5 RECENT DEVELOPMENT
10.2 COVANCE INC. (A SUBSIDIARY OF LABCORP)
10.2.1 COMPANY SNAPSHOT
10.2.2 REVENUE ANALYSIS
10.2.3 COMPANY SHARE ANALYSIS
10.2.4 SERVICE PORTFOLIO
10.2.5 RECENT DEVELOPMENTS
10.3 COGNIZANT
10.3.1 COMPANY SNAPSHOT
10.3.2 REVENUE ANALYSIS
10.3.3 COMPANY SHARE ANALYSIS
10.3.4 SOLUTION PORTFOLIO
10.3.5 RECENT DEVELOPMENT
10.4 ACCENTURE
10.4.1 COMPANY SNAPSHOT
10.4.2 REVENUE ANALYSIS
10.4.3 COMPANY SHARE ANALYSIS
10.4.4 SERVICE PORTFOLIO
10.4.5 RECENT DEVELOPMENTS
?
10.5 PAREXEL INTERNATIONAL CORPORATION
10.5.1 COMPANY SNAPSHOT
10.5.2 PRODUCT PORTFOLIO
10.5.3 RECENT DEVELOPMENTS
10.6 ORACLE
10.6.1 COMPANY SNAPSHOT
10.6.2 REVENUE ANALYSIS
10.6.3 SOLUTION PORTFOLIO
10.6.4 RECENT DEVELOPMENT
10.7 AB CUBE
10.7.1 COMPANY SNAPSHOT
10.7.2 SOLUTION PORTFOLIO
10.7.3 RECENT DEVELOPMENT
10.8 ARISMIDDLE EAST AND AFRICA
10.8.1 COMPANY SNAPSHOT
10.8.2 PRODUCT PORTFOLIO
10.8.3 RECENT DEVELOPMENTS
10.9 BIOCLINICA
10.9.1 COMPANY SNAPSHOT
10.9.2 SERVICE PORTFOLIO
10.9.3 RECENT DEVELOPMENTS
10.10 C3I
10.10.1 COMPANY SNAPSHOT
10.10.2 REVENUE ANALYSIS
10.10.3 SERVICE PORTFOLIO
10.10.4 RECENT DEVELOPMENTS
10.11 DRUG SAFETY SOLUTIONS LIMITED
10.11.1 COMPANY SNAPSHOT
10.11.2 SERVICE PORTFOLIO
10.11.3 RECENT DEVELOPMENT
10.12 ENNOV
10.12.1 COMPANY SNAPSHOT
10.12.2 PRODUCT PORTFOLIO
10.12.3 RECENT DEVELOPMENTS
10.13 ERGOMED PLC
10.13.1 COMPANY SNAPSHOT
10.13.2 REVENUE ANALYSIS
10.13.3 SERVICE PORTFOLIO
10.13.4 RECENT DEVELOPMENTS
?
10.14 GENPACT
10.14.1 COMPANY SNAPSHOT
10.14.2 REVENUE ANALYSIS
10.14.3 PRODUCT PORTFOLIO
10.14.4 RECENT DEVELOPMENTS
10.15 ICON PLC
10.15.1 COMPANY SNAPSHOT
10.15.2 REVENUE ANALYSIS
10.15.3 SERVICE PORTFOLIO
10.15.4 RECENT DEVELOPMENTS
10.16 IQVIA
10.16.1 COMPANY SNAPSHOT
10.16.2 REVENUE ANALYSIS
10.16.3 SOLUTION PORTFOLIO
10.16.4 RECENT DEVELOPMENTS
10.17 PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC.
10.17.1 COMPANY SNAPSHOT
10.17.2 SERVICE PORTFOLIO
10.17.3 RECENT DEVELOPMENTS
10.18 PHARMACEUTICAL RESEARCH ASSOCIATES INC.
10.18.1 COMPANY SNAPSHOT
10.18.2 REVENUE ANALYSIS
10.18.3 SOLUTION PORTFOLIO
10.18.4 RECENT DEVELOPMENTS
10.19 UNITED BIOSOURCE LLC
10.19.1 COMPANY SNAPSHOT
10.19.2 SERVICE PORTFOLIO
10.19.3 RECENT DEVELOPMENT
10.20 WORLDWIDE CLINICAL TRIALS
10.20.1 COMPANY SNAPSHOT
10.20.2 SERVICE PORTFOLIO
10.20.3 RECENT DEVELOPMENTS
11 QUESTIONNAIRE
12 RELATED REPORTS